Abstract
Major depressive disorder is a significant and costly cause of global disability. Until the discovery of the rapid acting antidepressant (RAAD) effects of ketamine, treatments were limited to drugs that have delayed clinical benefits. The mechanism of action of ketamine is currently unclear but one hypothesis is that it may involve neuropsychological effects mediated through modulation of affective biases (where cognitive processes such as learning and memory and decision-making are modified by emotional state). Previous work has shown that affective biases in a rodent decision-making task are differentially altered by ketamine, compared to conventional, delayed onset antidepressants. This study sought to further investigate these effects by comparing ketamine with other NMDA antagonists using this decision-making task. We also investigated the subtype selective GluN2B antagonist, CP-101,606 and muscarinic antagonist scopolamine which have both been shown to have RAAD effects. Both CP-101,606 and scopolamine induced similar positive biases in decision-making to ketamine, but the same effects were not seen with other NMDA antagonists. Using targeted medial prefrontal cortex (mPFC) infusions, these effects were localised to the mPFC. In contrast, the GABAA agonist, muscimol, induced general disruptions to behaviour. These data suggest that ketamine and other RAADs mediate a specific effect on affective bias which involves the mPFC. Non-ketamine NMDA antagonists lacked efficacy and we also found that temporary inactivation of the mPFC did not fully recapitulate the effects of ketamine, suggesting a specific mechanism.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
World Health Organization. Depression fact sheet. 2018. https://www.who.int/news-room/fact-sheets/detail/depression. Accessed 5 Nov 2019.
Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2000;14:3–20.
Zarate CA,Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS. et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.
Zarate CA,Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA. et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153–5.
DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA. et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605–11.
Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L. et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970–6.
Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ. et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depression Anxiety. 2014;31:335–43.
Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol. 2005;1:167–95.
Clark L, Chamberlain SR, Sahakian BJ. Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci. 2009;32:57–74.
Gotlib IH, Joormann J. Cognition and depression: current status and future directions. Annu Rev Clin Psychol. 2010;6:285–312.
Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology. 2003;28:148–52.
Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004;161:1256–63.
Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S. et al. Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol (Oxf, Engl). 2011;25:1159–67.
Harmer CJ, O’Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A. et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166:1178–84.
Stuart SA, Butler P, Munafo MR, Nutt DJ, Robinson ES. A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology. 2013;38:1625–35.
Harding EJ, Paul ES, Mendl M. Animal behaviour: Cognitive bias and affective state. Nature. 2004;427:312–312.
Robinson E, Roiser J. Affective biases in humans and animals. In: Robbins TW, Sahakian BJ, editors. Translational neuropsychopharmacology. Current topics in behavioral neurosciences, Vol. 28. Cham: Springer; 2015.
Mendl M, Burman OHP, Paul ES. An integrative and functional framework for the study of animal emotion and mood. Proc R Soc B: Biol Sci. 2010;277:2895–904.
Roelofs S, Boleij H, Nordquist RE, van der Staay FJ. Making decisions under ambiguity: judgment bias tasks for assessing emotional state in animals. Frontiers Behav Neurosci. 2016;10:119.
Neville V, Nakagawa S, Zidar J, Paul ES, Lagisz M, Bateson M. et al. Pharmacological manipulations of judgement bias: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2020;108:269–86.
Hales CA, Robinson ES, Houghton CJ. Diffusion modelling reveals the decision making processes underlying negative judgement bias in rats. PloS ONE. 2016;11:e0152592.
Parker RM, Paul ES, Burman OH, Browne WJ, Mendl M. Housing conditions affect rat responses to two types of ambiguity in a reward-reward discrimination cognitive bias task. Behav Brain Res. 2014;274:73–83.
Hales CA, Houghton CJ, Robinson ESJ. Behavioural and computational methods reveal differential effects for how delayed and rapid onset antidepressants effect decision making in rats. Eur Neuropsychopharmacol. 2017;27:1268–80.
Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP. et al. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study. Neuropsychopharmacology. 2017;42:844–53.
Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74:966–73.
Ates-Alagoz Z, Adejare A. NMDA receptor antagonists for treatment of depression. Pharmaceuticals (Basel). 2013;6:480–99.
Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631–7.
Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63:1121–9.
Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol. 2013;4:161.
Li CT, Chen MH, Lin WC, Hong CJ, Yang BH, Liu RS. et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp. 2016;37:1080–90.
Abdallah CG, De Feyter HM, Averill LA, Jiang L, Averill CL, Chowdhury GMI. et al. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018;43:2154–60.
Stuart SA, Butler P, Munafo MR, Nutt DJ, Robinson ES. Distinct neuropsychological mechanisms may explain delayed- versus rapid-onset antidepressant efficacy. Neuropsychopharmacology. 2015;40:2165–74.
Stuart SA, Robinson ESJ. Reducing the stress of drug administration: implications for the 3Rs. Sci Rep. 2015;5:14288.
Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research 2018;7:F1000 Faculty Rev-659.
Benn A, Robinson ES. Investigating glutamatergic mechanism in attention and impulse control using rats in a modified 5-choice serial reaction time task. PloS ONE. 2014;9:e115374.
Paxinos G, Watson C. The rat brain—in stereotaxic coordinates. San Diego, CA: Academic Press; 1998.
Bethell EJ. A “how-to” guide for designing judgment bias studies to assess captive animal welfare. J Appl Anim Welf Sci. 2015;18:S18–S42.
Baciadonna L, McElligott AG. The use of judgement bias to assess welfare in farm livestock. Anim Welf. 2015;24:81–91.
Polis AJ, Fitzgerald PJ, Hale PJ, Watson BO. Rodent ketamine depression-related research: Finding patterns in a literature of variability. Behav Brain Res. 2019;376:112153.
Gerhard DM, Pothula S, Liu RJ, Wu M, Li XY, Girgenti MJ et al. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. J Clin Invest. 2020;130:1336–1349.
Drewniany E, Han J, Hancock C, Jones RL, Lim J, Nemat Gorgani N. et al. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression. J Clin Pharm Ther. 2015;40:125–30.
Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–64.
Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R. et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74:742–9.
Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M. et al. GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. J Clin Invest. 2016;126:2482–94.
Murphy ER, Fernando ABP, Urcelay GP, Robinson ESJ, Mar AC, Theobald DEH. et al. Impulsive behaviour induced by both NMDA receptor antagonism and GABAA receptor activation in rat ventromedial prefrontal cortex. Psychopharmacology. 2012;219:401–10.
Ceglia I, Carli M, Baviera M, Renoldi G, Calcagno E, Invernizzi RW. The 5-HT receptor antagonist M100,907 prevents extracellular glutamate rising in response to NMDA receptor blockade in the mPFC. J Neurochem. 2004;91:189–99.
Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–7.
Eshel N, Roiser JP. Reward and punishment processing in depression. Biol Psychiatry. 2010;68:118–24.
Murrough JW, Iacoviello B, Neumeister A, Charney DS, Iosifescu DV. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. 2011;96:553–63.
Biselli T, Lange S, Sablottny L, Steffen J, Walther A. Optogenetic and chemogenetic insights into the neurocircuitry of depression-like behaviour: a systematic review. Eur J Neurosci. https://doi.org/10.1111/ejn.14603. [Epub ahead of print].
Hare BD, Shinohara R, Liu RJ, Pothula S, DiLeone RJ, Duman RS. Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nat Commun. 2019;10:223.
Author information
Authors and Affiliations
Contributions
C.A.H. performed the research, analysed data, wrote and edited the paper. J.M.B. performed research and analysed data. R.A. and B.H. designed the research and edited the paper. E.S.J.R. designed the research and wrote and edited the paper.
Corresponding author
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hales, C.A., Bartlett, J.M., Arban, R. et al. Role of the medial prefrontal cortex in the effects of rapid acting antidepressants on decision-making biases in rodents. Neuropsychopharmacol. 45, 2278–2288 (2020). https://doi.org/10.1038/s41386-020-00797-3
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41386-020-00797-3
